Business, energy, technology, markets and global industry news from Business News Today

traumatic brain injury

PharmaDeviceNews traumatic brain injury
Representative image: Researchers examine brain imaging and neural cell preparations as Hopstem’s hNPC01 receives FDA clearance for clinical trials targeting chronic motor disability after hemorrhagic stroke and traumatic brain injury.
Pharma & Biotech

FDA clears hNPC01 neural cell therapy trials for hemorrhagic stroke and traumatic brain injury

FDA clears Hopstem’s hNPC01 neural cell therapy for trials in hemorrhagic stroke and traumatic brain injury, with Fast Track status in both.

Read More
Pharma & Biotech

How PharmAla Biotech Holdings Inc. is positioning APA-01 around traumatic brain injury and neurorehabilitation

How is PharmAla Biotech Holdings Inc. positioning APA-01 for traumatic brain injury and neurorehabilitation markets? Read the full PDN analysis.

Read More
Pharma & Biotech

Why Oragenics, Inc. is betting on CardioDialysis technology to expand its TBI platform

Why is Oragenics, Inc. expanding into CardioDialysis for TBI treatment? Explore the strategy, risks, and future implications today.

Read More
Pharma & Biotech

Alpha Cognition expands ALPHA-1062 into traumatic brain injury, but approval is still a distant goal

Alpha Cognition won a U.S. patent for ALPHA-1062 in TBI. Read why the IP matters, what it changes, and where the biggest risks still remain.

Read More